Literature DB >> 19346518

Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor.

Randy O Odero, Kerry O Cleveland, Michael S Gelfand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19346518     DOI： 10.1093/jac/dkp127

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  5 in total

1.  Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy.

Authors:  J Parra-Ruiz; C Dueñas-Gutiérrez; C Tomás-Jiménez; J P Linares-Palomino; J Garrido-Gomez; J Hernández-Quero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-08       Impact factor: 3.267

2.  Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors.

Authors:  Christopher M Bland; P Brandon Bookstaver; Z Kevin Lu; Brianne L Dunn; Kathey Fulton Rumley
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

Review 3.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

4.  Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.

Authors:  Mao Hagihara; Takumi Umemura; Takeshi Mori; Hiroshige Mikamo
Journal:  Ther Clin Risk Manag       Date:  2012-02-17       Impact factor: 2.423

Review 5.  Drug induced rhabdomyolysis.

Authors:  Martin Hohenegger
Journal:  Curr Opin Pharmacol       Date:  2012-05-05       Impact factor: 5.547
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.